| Autor: |
Martins-Olivera BT; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Almeida-Reis R; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Theodoro-Júnior OA; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Oliva LV; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Neto Dos Santos Nunes N; Department of Biochemistry, Universidade Federal de São Paulo, 04044-020 São Paulo, SP, Brazil., Olivo CR; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Vilela de Brito M; Department of Biochemistry, Universidade Federal de São Paulo, 04044-020 São Paulo, SP, Brazil., Prado CM; Department of Bioscience, Federal University of Sao Paulo, 11015-020 Santos, SP, Brazil., Leick EA; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Martins Mde A; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Oliva ML; Department of Biochemistry, Universidade Federal de São Paulo, 04044-020 São Paulo, SP, Brazil., Righetti RF; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil., Tibério Ide F; Department of Clinical Medicine, School of Medicine, University of São Paulo, 01246-903 São Paulo, SP, Brazil. |
| Abstrakt: |
Background. Elastase mediates important oxidative actions during the development of chronic obstructive pulmonary disease (COPD). However, few resources for the inhibition of elastase have been investigated. Our study evaluated the ability of the recombinant plant derived Bauhinia bauhinioides Kallikrein proteinase Inhibitor (rBbKI) to modulate elastase-induced pulmonary inflammation. Methods. C57Bl/6 mice were given intratracheal elastase (ELA group) or saline (SAL group) and were treated intraperitoneally with rBbKI (ELA-rBbKI and SAL-rBbKI groups). At day 28, the following analyses were performed: (I) lung mechanics, (II) exhaled nitric oxide (ENO), (III) bronchoalveolar lavage fluid (BALF), and (IV) lung immunohistochemical staining. Results. In addition to decreasing mechanical alterations and alveolar septum disruption, rBbKI reduced the number of cells in the BALF and decreased the cellular expression of TNF-α, MMP-9, MMP-12, TIMP-1, eNOS, and iNOS in airways and alveolar walls compared with the ELA group. rBbKI decreased the volume proportion of 8-iso-PGF2α, collagen, and elastic fibers in the airways and alveolar walls compared with the ELA group. A reduction in the number of MUC-5-positive cells in the airway walls was also observed. Conclusion. rBbKI reduced elastase-induced pulmonary inflammation and extracellular matrix remodeling. rBbKI may be a potential pharmacological tool for COPD treatment. |
